FOCUS DAY - TUESDAY 22ND OCTOBER 2019
Enhancing Clinical Efficacy with Macrophage Checkpoint Blockades in Combination Therapies
9:00 am to 12:00 pm
To increase the clinical efficacy of immuno-oncology drugs, the field is exploring different combination rationales to see which therapeutic combination will have a synergistic effect when targeting cancers. However, there are still many uncertainties with questions around dosing, safety and scheduling.
This workshop will explore macrophage biology to identify which targeted pathways have a real science driven rationale for combination which will improve targeting, safety and overall response rate.
Join this workshop to:
• Review TG-1801 which is a novel, bispecific antibody currently in Phase 1 that selectively targets CD47 on CD19+ B-cells, sparing red blood cells or platelets, and blocking the CD47-SIRPα macrophage checkpoint on B cells
• Evaluate results that set the preclinical rationale for a combination strategy of the novel CD47-CD19 antibody TG-1801 with other B-cell targeted drugs, particularly umbralisib and ublituximab, in B-NHL
• Review the strategies that back up combinations in oncology, from chemotherapies cocktails to the more recent I/O combinations
Vice President, Preclinical Sciences
Emmanuel Normant is currently the vice president of preclinical sciences at TG Therapeutics, a biotech focused on heme malignancies and located in New York. There, he oversees the early pipeline that includes a novel BTK inhibitor, an anti-PD-1 antibody and a bispecific antibody directed against CD19 and CD47. All three drugs are currently tested in phase 1 dose-escalation clinical trials in hematologic cancers. Dr Normant joined TG Therapeutics two years ago, bringing in 20 years expertise in cancer biology, pharmacology, immuno-oncology, cancer epigenetic and preclinical sciences.
Translational Studies using Human Tumor Ex Vivo Culture During Development of Myeloid-Targeting Therapies
1:00 pm to 4:00 pm
The changing plasticity of macrophages is difficult to reproduce in animal models which lack comparable biology and immune systems.
This translational challenge limits the validation of proof of concepts and requires the field to explore different preclinical models to analyze the safety and activity of their drug target.
Join this workshop to:
• Understand motivation for developing ex vivo cultures to test macrophage-based therapies against human cancers
• Compare the advantages and disadvantages between tumor slice and tumor dissociated cultures
• Review Keytruda and macrophage-repolarizing agents’ response across multiple tumor types
• Leave understanding the implications of using human ex vivo tumor cultures for clinical translation
Co-Founder, Vice President & Head of Computational Biology
Igor Feldman is a Co-Founder and has served as a Vice President and the Head of Computational Biology at Verseau Therapeutics since January 2017. Igor has held positions at Merck & Co., Rosetta Informatics, Jounce Therapeutics and Epizyme. He has been involved in discovery and clinical development using large omics datasets of human tumors, drug response biomarker discovery, novel target discovery in immunooncology and epigenetics and establishing computational infrastructure from the ground up for early discovery and development support in several biotech startup companies. He is an inventor on eight U.S. patents.
Principal Scientist, Discovery Oncology
Yanyan Zheng is a Principal Scientist in Discovery Oncology at Merck & Co. Inc., leading the tumor intrinsic targeting and translational pathology group. As a seasoned drug hunter, she is interested in bringing innovative therapeutics to patients with unmet medical need. Her expertise encompasses a broad range of processes in drug development, from target identification/validation, biologics discovery, to translational research. Dr. Zheng received her Ph.D. in Molecular Microbiology and Immunology, with a concurrent M.S. degree in Biostatistics, from University of Southern California. She conducted her Postdoctoral Fellowship training in Cancer Biology at Stanford University.”